This suggests a role of Gpr183 in the interplay between intestinally located and circulating immune cells, accordingly, an antagonistic approach has already been raised with evidence in inflammatory bowel diseases and rheumatoid arthritis to impair autoimmune responses within the intestines [59, 60]. Here, GPR183 is linked to inflammatory bowel disease.